Collaboration Between The LYCRA Company and HeiQ Promises an Exciting Future for Textiles With a Focus on Stretch, Comfort, Freshness and Sustainability
15.7.2021 15:45:00 EEST | Business Wire | Press release
Textile technology innovation leaders, The LYCRA Company and HeiQ, have entered into a broad-based collaboration across multiple technology and brand platforms that promises to bring more innovative, quality-enhancing and sustainable textile technologies to consumers around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005642/en/
Leaders of The LYCRA Company & HeiQ announce collaboration. (Photo: Business Wire)
Building on exploratory discussions that started in early 2019, HeiQ and The LYCRA Company have elected to leverage their shared philosophies and strengths in textile science, commercial networks, and global marketing to drive innovation platforms into broad textile markets. The companies envision consumer-branded innovations in the stretch, thermoregulation, freshness and sustainability market spaces.
“We are pleased to announce the launch of this collaboration, the culmination of conversations that began two years ago,” commented Steve Stewart, chief brand and innovation officer at The LYCRA Company. “By combining the strength of both companies, we will continue to drive meaningful innovation within the textile industry, delivering new solutions at a quicker pace to a broader audience.”
Together, The LYCRA Company and HeiQ bring trusted expertise across the global textile value-chain of yarn processors, fabric mills, garment producers, brands and retailers and demonstrate a commitment to sustainable, consumer-driven innovations, delivered through partnerships, that take textile performance to unprecedented levels. These industry leaders have complementary strengths: whereas The LYCRA Company is the consumer-recognized leader in branded fibers and fabrics addressing needs for sustainable stretch, warming and cooling, HeiQ is a renowned innovator in finished-based innovations addressing freshness, sustainability, smart temperature management, antiviral, dryness, and many other market spaces.
The initial and first of many innovation platforms will roll out through the summer, bringing a new dimension of comfort and confidence to the consumer by delivering HeiQ freshness and antiviral benefits with the quality and comfort of stretch fabrics certified to perform with a new LYCRA ® freshFX ® technology brand standard. Preparation for this innovation is already underway, with an initial focus on Chinese local value chains for the Chinese consumer, and the introduction is earmarked for the Intertextile show in Shanghai at the end of August.
“Our goal at HeiQ is to enable brands and mills in the textile industry to bring more comfort, performance and sustainability to textile products while raising brand awareness with key consumers who will benefit the most from these innovations,” noted Carlo Centonze, co-founder and CEO of HeiQ Group. “This collaboration with The LYCRA Company not only brings the best minds together but also ensures our breakthrough innovations will be available for and benefit as many consumers as possible.”
“The collaboration is based on a strong foundation of common values and philosophies shared by our two companies,” said Julien Born, CEO at The LYCRA Company. “We look forward to exploring the natural synergies between us and uncovering new solutions for the apparel industry.”
The focus of these collaborations will be to address relevant consumer needs for quality, durability, and sustainable garments. Sample fabrics and garments will be available in late summer for commercial selection.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA ® , LYCRA HyFit ® , LYCRA ® T400 ® , COOLMAX ® , THERMOLITE®, ELASPAN®, SUPPLEX ® , and TACTEL ® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA ® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.
LYCRA ® freshFX ® is trademark of The LYCRA Company.
About HeiQ
Founded in 2005 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH) and listed on the London Stock Exchange Main Market (LSE:HEIQ), HeiQ is a leader in textile and materials innovation creating some of the most effective, durable and high-performance technologies on the market today. HeiQ strives to improve the lives of billions of people through pioneering textiles and materials innovation. Combining three areas of expertise – scientific research, specialty materials manufacturing and consumer ingredient branding – HeiQ is the ideal innovation partner to create differentiating and sustainable products and capture the added value at the point of sale. With its 14 offices, 7 manufacturing sites and 7 R&D hubs, HeiQ today employs 190 professionals. It has a total capacity of 45,000 tons of specialty chemicals per year and serves over 1,000 industrial customers in over 60 countries. Today, HeiQ’s consumer goods and medical devices can be found in 56 countries. For more information, visit www.heiq.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005642/en/
Contact information
Karie Ford
karie.j.ford@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom